Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-25-206203

Chief Scientific Officer sold 8,500 shares at an average $24.19 ($205,649)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Bredt David Chief Scientific Officer 2025-09-15 Sale 10b5-1 −5,098 $23.88 $121,761 421,544 D
Bredt David Chief Scientific Officer 2025-09-15 Sale 10b5-1 −3,402 $24.66 $83,888 418,142 D
Open-market sales · 8,500 sh · avg $24.19 · $205,649
Loading xslF345X05/ownership.xml…